DrugPatentWatch Database Preview
Sofosbuvir; velpatasvir; voxilaprevir - Generic Drug Details
What are the generic sources for sofosbuvir; velpatasvir; voxilaprevir and what is the scope of freedom to operate?
Sofosbuvir; velpatasvir; voxilaprevir
is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Sofosbuvir; velpatasvir; voxilaprevir has five hundred patent family members in forty-eight countries.
There are nine drug master file entries for sofosbuvir; velpatasvir; voxilaprevir. One supplier is listed for this compound.
Summary for sofosbuvir; velpatasvir; voxilaprevir
| International Patents: | 500 |
| US Patents: | 15 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 9 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 10 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for sofosbuvir; velpatasvir; voxilaprevir |
| DailyMed Link: | sofosbuvir; velpatasvir; voxilaprevir at DailyMed |
Recent Clinical Trials for sofosbuvir; velpatasvir; voxilaprevir
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Partners in Health | Phase 4 |
| Kirby Institute | Phase 4 |
| Johns Hopkins University | Phase 1 |
See all sofosbuvir; velpatasvir; voxilaprevir clinical trials
Recent Litigation for sofosbuvir; velpatasvir; voxilaprevir
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc. | 2018-03-27 |
| GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED | 2018-03-14 |
| Idenix Pharmaceuticals LLC v. Gilead Sciences, Inc. | 2014-07-01 |
See all sofosbuvir; velpatasvir; voxilaprevir litigation
PTAB Litigation
| Petitioner | Date |
|---|---|
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | 2017-12-26 |
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | 2017-11-09 |
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. | 2017-11-02 |
Pharmacology for sofosbuvir; velpatasvir; voxilaprevir
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 200904453 | Start Trial |
| Chile | 2014003634 | Start Trial |
| Denmark | 2552930 | Start Trial |
| Eurasian Patent Organization | 201171417 | Start Trial |
| Spain | 2644990 | Start Trial |
| Israel | 217228 | Start Trial |
| Colombia | 7160104 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for sofosbuvir; velpatasvir; voxilaprevir
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2203462 | C300704 | Netherlands | Start Trial | PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117 |
| 2203462 | C20140035 00135 | Estonia | Start Trial | PRODUCT NAME: SOFOSBUVIIR;REG NO/DATE: EU/1/13/894 17.01.2014 |
| 2203462 | PA2014040 | Lithuania | Start Trial | PRODUCT NAME: SOFOSBUVIRUM; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116 |
| 2203462 | 300704 | Netherlands | Start Trial | PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117 |
| 2203462 | 1490066-6 | Sweden | Start Trial | PRODUCT NAME: SOFOSBUVIR; REG. NO/DATE: EU/1/13/894 20140117 |
| 2203462 | PA2014040,C2203462 | Lithuania | Start Trial | PRODUCT NAME: SOFOSBUVIRAS; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116 |
| 2203462 | CA 2014 00061 | Denmark | Start Trial | PRODUCT NAME: SOFOSBUVIR; REG. NO/DATE: EU/1/13/894/001-002 20140116 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.